Introduction {#Sec1}
============

Dyslipidemia represents one of the major risk factors for atherosclerosis affecting arteries of large and medium size and consequently causing ischemia in the brain, heart, or legs. Coronary artery disease and cerebral stroke represent the major causes of morbidity and mortality among elderly and middle aged subjects \[[@CR1]\]. The prevalence of dyslipidemia has increased dramatically in Chinese cities with lifestyle changes over the past decade, and cardiovascular diseases have emerged as a leading cause of death in Chinese adults \[[@CR2]\].

Surveys investigating the epidemiological data of dyslipidemia in Chinese adults have been published, but the results vary due to diverse populations of different regions and the use of different diagnosis criteria \[[@CR2]\]. An overall appraisal of dyslipidemia epidemiology nationwide in China would potentially benefit future research and policy discussions. We therefore performed meta-analyses by a comprehensive systematic review of all available evidence to synthesize the current dyslipidemia prevalence, awareness, treatment, and control among Chinese adults.

Methods {#Sec2}
=======

Search strategy and eligibility criteria {#Sec3}
----------------------------------------

Based on the MOOSE guideline \[[@CR3]\], we identified epidemiological studies on dyslipidemia in Chinese adults published in English or Chinese between January 2003 and August 2013. The search strategy comprised of a search of Western electronic databases (including Medline, Embase, and CINAHL) and a search of Chinese databases (including SinoMed, CNKI, and Wanfang Data). We used the search terms "dyslipidemia", "hyperlipidemia", "epidemiology", "incidence", "prevalence", "awareness rate", "treatment rate", "control rate", "China or Chinese", and these terms' variants and combinations.

Eligible studies had to have reported any of the following epidemiological data related to dyslipidemia in sampled populations of Chinese subjects: prevalence, awareness rate, treatment rate, and control rate. The diagnosis criteria was based on the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults \[[@CR2]\], which defined dyslipidemia as any one of the following four conditions: hypercholesterolemia (total cholesterol (TC) ≥ 6.22 mmol/L); hypertriglyceridemia (triglycerides (TG) ≥2.26 mmol/L); low levels of high-density lipoprotein cholesterol (HDL-C \< 1.04 mmol/L); high levels of low-density lipoprotein cholesterol (LDL-C ≥ 4.14 mmol/L).

Dyslipidemia awareness was defined as a self-report of any prior laboratory diagnosis of dyslipidemia. Treatment was defined broadly as interventions including medication, diet, exercise, and monitoring to manage dyslipidemia. Participants were considered to have controlled dyslipidemia if their serum TC, TG, LDL-C, and HDL-C were within the normal ranges as defined above based on the 2007 Chinese guidelines.

We also applied the following exclusion criteria in filtering the identified publications:Non-human studiesNon-research based publications such as press releases, newsletters, forum discussions, etc.Non-epidemiological studies such as basic science research on dyslipidemia.Studies that did not disclose when the data was collected, sample size, or denominator for each reported prevalence or rate.Studies that investigated specific populations such as military, prisoners, specific ethnic groups, etc.Studies that did not apply the diagnosis criteria published in the 2007 Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults.

Study identification and data extraction {#Sec4}
----------------------------------------

We identified relevant studies by searching electronic databases, scanning reference lists, and consulting clinical experts in dyslipidemia. Additionally, studies presented at key conference proceedings were identified. Two reviewers independently examined all the titles and abstracts of the studies retrieved from the searches for potentially eligible studies, then the full text of all potentially relevant citations were obtained and independently assessed by the reviewers to confirm whether they met the inclusion criteria. The results were checked and discussed by the two reviewers to agree upon a final list of included studies.

Using a standardized and predesigned data collection form, all relevant data in each included paper were extracted by two reviewers independently. The data extracted were cross-checked and any unresolved discrepancies were referred to a third reviewer. Where necessary, inputs of a clinical expert advisor were solicited to facilitate discussions among the reviewers.

For each included study, we extracted general information (including authors, year, title, type of publication, etc.), study characteristics (including study design, population, location, diagnosis criteria, sample size, etc.), participants' characteristics (including age, sex, type of dyslipidemia, etc.). We further recorded the numbers of people with any one type of dyslipidemia condition and reported awareness, treatment, and control rates. The data stratified by sex and dyslipidemia types, where available, were also extracted.

To inform the appropriateness of included studies in the meta-analysis and later evaluate the strength of the evidence, the two reviewers independently assessed and agreed on the quality of each included study using the quality assessment checklist for epidemiological studies \[[@CR4]\]. The checklist assesses the quality of studies on a scale of 0 (the worst) to 18 (the best) using predefined criteria on both internal and external validities \[[@CR4]\].

Statistical analyses and heterogeneity test {#Sec5}
-------------------------------------------

Pooled estimates of the dyslipidemia prevalence, awareness rate, treatment rate, and control rate and their corresponding 95% confidence intervals (CI) were calculated based on the random effect model \[[@CR5]\] and stratified by sex and age group (over 18 or over 30 years) where applicable. Heterogeneity between studies was evaluated with the Cochran's Q test and I^2^ statistic, which describes the percentage of variation across studies (values of 25%, 50%, and 75% indicate low, moderate, and high degrees of heterogeneity, respectively) \[[@CR6],[@CR7]\]. Subgroup analyses were performed to investigate potential sources of heterogeneity from different geographical regions and types of dyslipidemia. Publication bias was evaluated by using the funnel plots method. Furthermore, sensitivity analyses were performed to evaluate the influence of particular study on a pooled estimate, which was recalculated by omitting a study each time. Independent or paired t-tests were used as appropriate, and a significant difference was reported if the p-value was less than 0.05. All statistical analyses were performed using SPSS version 20.0 (SPSS Inc, Chicago, USA) and Comprehensive Meta-Analysis software version 2.0 (Biostat, Englewood, USA).

Results {#Sec6}
=======

Characteristics of included studies {#Sec7}
-----------------------------------

Our searches retrieved 7669 citations. Of these, 6800 were excluded after reading the abstracts, and 831 were further excluded after assessing the full papers, leaving 38 eligible papers for inclusion in our review and analyses (Figure [1](#Fig1){ref-type="fig"}) \[[@CR8]-[@CR45]\], which involved a total of 387,825 Chinese people.Figure 1**Flow chart of screening and inclusion of studies for review and analysis.**

Among the 38 included papers, 36 were written in Chinese and two were written in English; 33 studies were cross-sectional surveys and five studies employed census surveys or other designs; 18 studies were conducted in eastern China, 10 studies were conducted in central China, eight studies were conducted in western China, and two surveys crossed regions nationwide (Table [1](#Tab1){ref-type="table"}) \[[@CR8]-[@CR45]\].Table 1**Characteristics of included studiesAuthorYearRegionAge rangeNumber of participantsNumber of patients diagnosed with dyslipidemiaScore of quality assessment**Luo R2009Chongqing18-59 y20000646412Guo MH2011Beijing18-79 y6790323110Li Y2008Beijing18-79 y2776126915Luo WP2010-2011Xinjiang≥ 18 y2999227714You AG2007-2008Henan≥ 18 y20194-15Li JH2010National≥ 18 y97409-15Mo J2010Guangdong≥ 18 y3577217316Pang QY2006Henan≥ 18 y9843149Pang QY2007Henan≥ 18 y10127439211Li JH2010National≥ 18 y974095181815Chen YY2010Jiangxi≥ 18 y3000182114Zhang XW2010Zhejiang≥ 18 y17437869414Li XH2007-2008Gansu\> 18 y303879314Hu XL-Zhejiang\> 18 y2036-12Li SL2007-2008Shanxi20-74 y128645914Gao B2007-2008Shanxi20-74 y3298110615Jin LZ2007Guangdong20-74 y1134-12Li J2009Beijing20-78 y4332100813Wang JH2007Beijing≥ 20 y10054-13Fu YY2007Beijing≥ 20 y10054337316Yin L2008-2009Hunan\> 20 y15446958Fu YY2007Beijing\> 20 y9786334714Guang ZJ2011Beijing21-91 y334099314Liu XY2008Ningxia≥ 25 y127561914Yuan XH-Guangdong\> 30 y10534658Liao XY2010Sichuan35-70 y203247414Wang CJ-Henan35-78 y16926748014Shao YQ2008Zhejiang\> 35 y7194-15Zhou WJ2008-2009Jiangsu\> 35 y210292214Li J2009Shandong\> 35 y1972-15Li Y2008Hubei\> 35 y9865279416Gao Y2011Jilin40-70 y133261812Liu DW-Henan≥ 45 y4779-12Zhao YZ-Sichuan\> 45 y20011311Wu ZF2007-2008Tianjin50-94 y1424-11Sheng L2009Beijing\> 60 y2685-13Hu XZ2007Henan\> 60 y124734713Liang YQ2011Guangdong\> 60 y113568012

Study quality was assessed for the 38 included papers. Four papers had quality scores between eight and 10 points, 13 papers had scores between 11 and 13 points, and 21 papers had scores between 14 and 16 points. Overall study quality was upper-middle and high, and the study quality did not differ significantly among the included studies.

Prevalence of dyslipidemia {#Sec8}
--------------------------

Twenty-eight papers reported the total numbers of participants in the studies and those who were diagnosed with dyslipidemia (Figure [2](#Fig2){ref-type="fig"}). The pooled prevalence of dyslipidemia in Chinese adults was 41.9% (95% CI: 37.7% -- 46.2%). The t-tests showed there were no statistically significant differences between subgroups stratified by age and geographic region (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}); however, the pooled prevalence of dyslipidemia in males (43.2%) was higher than in female (35.6%) with statistical significance (t = 3.08, p \< 0.05).Figure 2**Forest plot of 28 studies' reported prevalence of dyslipidemia.**Table 2**Prevelance of dyslipidemia by different age groupsAge rangeNumber of studiesTotal numbers of participantsMedian (%)Minimum (%)Maximum (%)Pooled prevalence (%) (95% CI)**≥ 18 y1920305243.423.375.942.4 (37.2 \~ 47.7)≥ 30 y93589244.223.359.940.9 (33.7 \~ 48.5)Total282389444423.375.941.9 (37.7 \~ 46.2)Table 3**Prevalence of dyslipidemia by different regions and sexesGroupsNumber of studiesTotal number of participantsMedian (%)Minimum (%)Maximum (%)Pooled prevalence (%) (95% CI)≥ 18 y**SexMale158014544.325.868.945.6 (40.0 \~ 51.4)Female159686433.714.656.435.9 (29.5 \~ 42.8)RegionEastern China8580924023.360.740.0 (32.6 \~ 47.9)Central China41565544.231.960.745.1 (35.2 \~ 55.5)Western China63189634.626.175.941.9 (28.9 \~ 56.1)**≥ 30 y**SexMale3544226.224.945.331.5 (20.7 \~ 44.8)Female3777230.229.94334.1 (26.1 \~ 43.3)RegionEastern China3429044.243.959.949.3 (39.4 \~ 59.3)Central China42937036.327.846.436.3 (26.6 \~ 47.1)Western China2223239.923.356.538.5 (13.1 \~ 72.2)**Total**SexMale188558743.724.968.943.2 (37.4 \~ 49.1)Female1810463632.714.656.435.6 (30.0 \~ 41.7)RegionEastern China116238244.223.360.742.5 (36.1 \~ 49.2)Central China84502543.827.860.740.6 (33.9 \~ 47.7)Western China83412834.623.375.941.0 (30.0 \~ 53.0)

In terms of the different types of dyslipidemia, the pooled prevalence estimates of hypercholesterolemia (TC), hypertriglyceridemia (TG), mixed hyperlipidemia (TC + TG), low levels of high-density lipoprotein cholesterol (HDL-C), and high levels of low-density lipoprotein cholesterol (LDL-C) are 10.1% (95% CI: 5.8% -- 16.9%), 17.7% (95% CI: 14.0% -- 22.1%), 5.1% (95% CI: 3.1% -- 8.2%), 11.0% (95% CI: 8.0% -- 15.0%), and 8.8% (95% CI: 54.1% -- 17.8%), respectively. There were no significant differences between age groups within each type of dyslipidemia condition (Table [4](#Tab4){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}).Table 4**Prevelance of dyslipidemia by different dyslipidemia typesTypesAge groupNumber of studiesTotal number of participantsMedian (%)Minimum (%)Maximum (%)Pooled prevalence (%) (95% CI)**Hypercholesterolemia (TC)≥ 18 y91433507.72.541.87.9 (4.6 \~ 13.2)≥ 30 y104136610.84.948.112.5 (5.8 \~ 25.0)Total191847168.22.548.110.1 (5.8 \~ 16.9)Hypertriglyceridemia (TG)≥ 18 y914335015.34.536.913.7 (10.7 \~ 17.4)≥ 30 y104136718.811.744.522.1 (16.0 \~ 29.7)Total1918471717.14.544.517.7 (14.0 \~ 22.1)Mixed hyperlipidemia (TC + TG)≥ 18 y3112496.51.94.24.8 (2.4 \~ 9.2)≥ 30 y12102\-\-\--Total4133516.41.98.35.1 (3.1 \~ 8.2)Low blood high-density lipoprotein cholesterol (HDL-C)≥ 18 y91433506.90.257.311.0 (6.9 \~ 16.9)≥ 30 y93812910.11.632.811.0 (6.6 \~ 17.9)Total18181479100.257.311.0 (8.0 \~ 15.0)High blood low-density lipoprotein cholesterol (LDL-C)≥ 18 y51308263.12.367.57.6 (2.1 \~ 24.3)≥ 30 y72984312.21.721.39.7 (4.5 \~ 19.8)Total121606698.81.767.58.8 (4.1 \~ 17.8)

Dyslipidemia awareness, treatment, and control {#Sec9}
----------------------------------------------

Using the dyslipidemia awareness rates reported in four studies, we arrived at a pooled estimate of 24.4% (95% CI: 14.4% -- 38.4%). Based on the reported dyslipidemia treatment rates in two studies, we estimated a pooled treatment rate of 8.8% (95% CI: 7.7% -- 10.0%). There were no significant differences between males and females in terms of dyslipidemia awareness and treatment rates (Table [5](#Tab5){ref-type="table"}). Only one paper reported a dyslipidemia control rate, which was 4.3% (3.1% for males and 5.5% for females).Table 5**Dyslipidemia awareness and treatment ratesGroupsNumber of studiesTotal number of participantsMedian (%)Minimum (%)Maximum (%)Pooled prevalence (%) (95% CI)Awareness rate**Male3280212512.425.320.1 (11.2 \~ 33.3)Female32843931.214.732.925.2 (13.0 \~ 43.1)Total45980728.913.529.824.4 (14.4 \~ 38.4)**Treatment rate**Male2266207.26.87.67.6 (7.3 \~ 7.9)Female22646710.99.212.510.6 (7.8 \~ 14.2)Total2530879.18.49.78.8 (7.7 \~ 10.0)

Sensitivity analysis, publication bias and heterogeneity {#Sec10}
--------------------------------------------------------

Two studies were assessed with a quality score of eight, the lowest among the included studies. In the sensitivity analysis, omitting these two studies resulted in a slight change in the pooled dyslipidemia prevalence estimate, 41.7% from 41.9%. The pooled prevalence of TC, TG, HDL-C, and LDL-C changed to 9.4%, 17.0%, 10.7%, and 8.3% from 10.1%, 17.7%, 11.0%, and 8.8%, respectively. Funnel plots were produced for the prevalence of each type of dyslipidemia (see the Additional file [1](#MOESM1){ref-type="media"}). Asymmetric funnels suggest the possibility of publication bias. A moderate degree of heterogeneity was observed in the pooled dyslipidemia prevalence (I^2^ = 49.9%, Q = 1.00, P \< 0.001), awareness rate (I^2^ = 49.9%, Q = 0.99, P \< 0.001), and treatment rate (I^2^ = 38.0%, Q = 0.721, P = 0.098).

Discussion {#Sec11}
==========

Our systematic review included 38 observational studies conducted in the past decade, covering most of the regions in China, and involving a total of 387,825 participants, representing the adult Chinese population. The pooled estimates from the meta-analyses showed high prevalence of dyslipidemia and low awareness, treatment, and control rates. The study and results are timely, as currently there is a lack of published up-to-date nationwide epidemiological data of dyslipidemia to support the evidence-based approach and management of dyslipidemia in China.

The pooled estimate of dyslipidemia prevalence among Chinese adults is 41.9%, which has more than doubled in the last 10 years \[[@CR46]\], approaching the reported prevalence of 53% from the US National Health and Nutrition Examination Survey 2003--2006 \[[@CR47]\]. The observed increase of dyslipidemia prevalence in China could possibly be attributed to the increasingly aging population and dramatic lifestyle changes coupled with economic growth, especially changes in cigarette smoking, dietary, and alcohol drinking behaviors among the general population \[[@CR48]\].

The study discovered that hypertriglyceridemia (TG) was the most prevalent form of dyslipidemia, with a pooled estimate of 17.7%, followed by low levels of blood high-density lipoprotein cholesterol (HDL-C) (11.0%), hypercholesterolemia (TC) (10.1%), high levels of low-density lipoprotein cholesterol (LDL-C) (8.8%), and mixed hyperlipidemia (TC + TG) (5.1%). As dyslipidemia is one of the well-established risk factors for cardiovascular diseases \[[@CR47]\], these results highlight the extensive need for appropriate interventions, both clinical and non-clinical, to treat all types of dyslipidemia. In addition, other considerations such as improving general awareness about dyslipidemia among both patients and health care professionals and promoting healthy diet and lifestyles are equally important in designing and implementing relevant public health strategies.

We calculated and compared the pooled estimates of dyslipidemia prevalence in age groups over 18 years and over 30 years. No significant difference was found between these age groups across different types of dyslipidemia conditions. However, trends of higher prevalence of TC, TG, and LDL-C abnormalities were observed in studies of older participants (≥30 years old) compared to those studies that enrolled younger participants (≥18 years old). We observed the highest estimate at 49.3% (95% CI: 39.4-59.3) among all of the pooled prevalence estimates in people over 30 years old in the eastern region of China. Another study in China concluded that greater burden of diet-related chronic conditions including dyslipidemia has been observed in economically vibrant and highly urbanized areas \[[@CR49]\], which are predominantly in the eastern coastal region. More economically developed areas tend to have better access to health care facilities, which might have contributed to diagnosis and hence higher reported prevalence rates in these studies among populations in the eastern region of China.

The systematic review showed that dyslipidemia is more common in men than in women, which is consistent with the findings from American population-based studies \[[@CR50],[@CR51]\]. There were no significant differences in awareness, treatment, and control rates between the groups of men and women in China. However, studies conducted in the US showed that dyslipidemia was treated and controlled less often in men than in women \[[@CR50]\]. A possible explanation for the higher dyslipidemia prevalence observed in men could be their higher probability of cigarette smoking, alcohol, and consumption of foods high in cholesterol.

The quality of studies included in our systematic review were generally good, thus the sensitivity analysis did not demonstrate much difference in the results of meta-analyses when the studies with the lowest quality scores were removed in the analyses. We believe our searches were comprehensive, although the asymmetric funnel plots suggested the possibility of publication bias. The moderate heterogeneity observed could come from the different study settings and populations. We investigated possible sources and performed subgroup analyses, but that still inadequately explained the heterogeneity findings in this study. The recent research of heterogeneity suggested that I^2^ estimates need to be interpreted with caution when a meta-analysis only includes a limited number of events or trials, in particular when the number of studies for further subgroup analyses is small \[[@CR52]\]. Nevertheless, these uncertainties indicate the need of a higher-quality national survey with larger samples with better represented coverage across China.

Our study has some limitations. First, all the included studies were published after 2007 as we used the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults, published in 2007, as the diagnosis criteria \[[@CR2]\]. Studies published before 2007 were based on a different set of diagnosis criteria, and therefore have not been included in our meta-analyses. Secondly, we could not investigate the differences in dyslipidemia prevalence between rural and urban areas due to the limited information reported in the included studies. Furthermore, we would like to highlight that the meta-analysis results on awareness, treatment, and control rate need to be interpreted with caution, as the number of studies reporting the relevant data are relatively small.

Conclusions {#Sec12}
===========

The pooled estimate of dyslipidemia prevalence among Chinese adults was 41.9%, and hypertriglyceridemia (TG) is the most prevalent dislipidemia condition. The prevalence of dyslipidemia in males was higher than in females. Our study also showed low dyslipidemia awareness, treatment, and control rates in China.

Additional file {#Sec13}
===============

Additional file 1:**Forest plots and funnel plots of different sets of analyses are available as appendices at** ***PHM*** **online.**
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